TL;DR
The 2027 Medicare Advantage star ratings landed, and they reallocated 2028 profit across the sector in a single session: Humana's 4+ star share went from 41% to 93%, sending the stock to a 52-week high, while Alignment Healthcare lost three-quarters of its bonus-eligible membership and threatened to sue. The through-line from last cycle's digest strengthens — MA profitability is administratively determined (quality scores → bonus dollars → margin), and this release is the cleanest proof yet. Meanwhile the Eighth Circuit heard the Arkansas PBM pharmacy-ownership ban, the one structural threat to the vertically integrated pharmacy flywheel that the FTC's conduct-only settlements left standing.
Star ratings: CMS just redistributed 2028's MA profit pool
The 2027 star ratings release was the sector's biggest single repricing event of the cycle, and it moved money by administrative formula, not by premium or denial policy.
"Could net Humana $3 billion or more in extra revenue in 2028."
— TD Cowen's Ryan Langston in Star Ratings Reprice the Sector
The numbers are stark. The average rating slipped to 3.99 from 4.01, and only about 37% of MA plans with drug coverage earned 4+ stars for 2027, down from 44% — the predictable result of CMS's tightened methodology (new measures, reweighted existing ones, raised cutpoints). The winners/losers table from Healthcare Dive's analysis: Humana 41%→93% (company figure: 95%, "up from just 20% in 2026"); UnitedHealth 81%→68%; CVS/Aetna 84%→67%; Alignment 98%→25%; HCSC 52%→13%. Evercore ISI's Elizabeth Anderson puts Humana's 2028 bonus at $4.8 billion (CNBC).
This is the topic's thesis in its purest form: a quality-rating release — not a premium hike, not a denial-policy change — moved Humana's equity by billions in one session because the 4-star threshold gates bonus payments and rebate flexibility. The "insurers just deny claims and pocket premiums" narrative misses this mechanism entirely; the profit engine is the regulated bonus architecture.
What to watch: Alignment's threatened litigation — its president Dawn Maroney said, "We intend to pursue all available administrative remedies and to litigate the measures and methodologies we believe warrant review," which would open a new front testing the 2027 methodology changes (watch the thread).
Humana: the reversal is real, but read the fine print on where the bonus goes
Humana's margin-compression story — a 0.9% net margin, stars collapsing from 94% of members in 4+ star plans in 2024 to 20% in 2026 — just reversed, and the tape noticed.
"The boost to profits will depend on reinvestment in member benefits and arrangements with healthcare providers."
— Baird in Humana's Stars Reversal
The stock jumped 11.6% in a day to $431.87, a 52-week high on 3.3x average volume, now 45.8% above its 200-day moving average at a 40.8 P/E — against trailing fundamentals of negative Q2 operating cash flow (-$426M) (HUM market view). J.P. Morgan's Lisa Gill called it "a clear win for a company that has been working toward this outcome for several years" (CNBC). The Baird caveat is the honest one: bonus dollars largely get bid back into benefits to compete for members — that's how the MA bonus mechanism works, and it's why a $3–4.8B revenue windfall doesn't translate dollar-for-dollar into margin.
What to watch: Whether Humana's 2027 benefit bids for the 2028 bonus year reinvest the windfall competitively — the spread between bonus revenue and reinvestment is the actual margin recovery.
UnitedHealth: the stars step-down sets up tomorrow's MCR test
UnitedHealth reports Q3 on October 13 with two moving parts stacked on each other: a dented quality-bonus pipeline and a medical-care-ratio guide that decides whether the margin rebuild holds.
"Manageable, especially because their enrollment in 4-plus star plans is still at the higher end compared to their peers."
— J.P. Morgan's Lisa Gill in UnitedHealth: Stars Step-Down
UNH's 4+ star share fell from 81% to 68% (J.P. Morgan estimates ~67%), the 2028 bonus drag landing on top of the 2027 contraction already formalized — 390,000 members' plans discontinued, Leerink estimating ~13% of plans dropped across 18 states. The stock sits at $379.30, down 17.3% from its July high, though the company has beaten estimates four straight quarters, most recently Q2 EPS of $6.38 versus $4.94 expected (UNH market view). The setup extends last cycle's framing: the popular narrative centers on denials and vertical-integration power, while what investors will actually parse tomorrow is a regulated MLR guide (88.1% ±25bps, with above 88.35% signaling pressure), reserve development, and the CMS-dented bonus pipeline. The Optum services leg, not the insurance margin, remains where the structural profit sits.
What to watch: Tomorrow's print — anything above an 88.35% MCR guide means Q4 spending has no room, and the margin-rebuild story wobbles (watch the thread).
The PBM structural threat gets its day in court — at the state level, not the federal one
With the FTC's case resolved into conduct remedies (per last cycle's digest), the only live structural threat to PBM vertical integration is now a constitutional question in the Eighth Circuit.
"When pharmacy benefit managers own their own pharmacies, that creates an irresistible opportunity for those PBMs to engage in predatory and anti-competitive practices."
— Arkansas attorney Joseph Nelson in PBM Pharmacy-Ownership Bans
The September 22 oral argument in Express Scripts v. Richmond framed the vertical-integration question at its purest. PBM counsel Jeffrey B. Wall called the law "as clear a violation as this court will ever see" under the Dormant Commerce Clause, quoting a sponsor — "we don't want these big companies, these big box stores, sucking our business and taking it out of Arkansas" — and flagging last-minute Walmart carve-outs as showing the law's true target. The stakes: "You're talking one-in-five Arkansans who're going to have to find a different place to get their medicines," with upwards of 50 pharmacy closures affecting five to six million prescriptions a year in the record. A ruling either way sets the constitutional template for whether states can force divestiture of the integrated pharmacy flywheel — the part of the PBM profit center state governments can actually reach, alongside spread-pricing enforcement like Arkansas Act 990's $10,000-per-violation damages. The panel's two Trump appointees pressing the state suggests it's genuinely contested.
What to watch: The Eighth Circuit ruling, expected in the coming months — it either constitutionalizes the ownership-ban playbook for other states or forecloses it.
What surprised us
- The sector's biggest profit event of the cycle was a spreadsheet release. CMS publishing star ratings moved Humana by billions in a day — no drug launch, no acquisition, no premium change. MA margins are administratively determined, and no popular narrative about insurers captures that.
- The giants' stars step-down barely dented the bull case. UNH down 13 points of 4-star share, CVS down 17 — and the analyst read is "manageable" because both still sit near the top of the peer table (Healthcare Dive). Scale in the bonus system is its own cushion.
- Alignment's collapse may produce the next litigation wave. The company lost 73 points of 4+ star share in one release and immediately threatened to sue — the same playbook Humana ran (and lost) on the 2025 ratings.
- The Walmart carve-out is the tell. The PBM side's own argument that Arkansas's law was protectionist rests on the state exempting the biggest retail pharmacy in America — vertical-integration politics makes for strange alliances on both sides (Courthouse News).
Open threads worth a vote
How Health Insurers Actually Make Money — delta briefing
Since last time
Promoted
- Humana — last cycle it was a supporting character in the MA-exits story (plan cuts, 91.3rd percentile of its 52-week range). Now it's a core section: the star ratings reversal made it the sector's biggest winner.
- The Arkansas PBM ownership ban / Eighth Circuit — previously a one-line "stalled" mention in the regulatory roundup. Now a full section: oral argument heard September 22, ruling pending, and it's the last live structural threat to PBM vertical integration.
Escalated
- The UnitedHealth Q3 MCR test — it was the prior briefing's sole open thread; now it's tomorrow's actual event (October 13), with a second variable stacked on top: the stars step-down dents the 2028 bonus pipeline ahead of the print.
Demoted
- The FTC/OptumRx settlement endgame — was a full section; now a single framing clause ("resolved into conduct remedies"). The rebate pass-through details, Florida AG suit, and Patients Before Monopolies Act are gone with it.
- UnitedHealth's 2027 plan-contraction specifics — was its own section; now compressed to two supporting data points (390,000 members, Leerink's ~13% of plans across 18 states) inside the escalated UNH section.
Disappeared
- Cigna entirely — the "market charging for a risk that keeps not arriving" section (11.18 P/E, $270.53 vs. $342.29 target, Q2 cash-flow seasonality) is absent from this briefing.
- Centene entirely — the 3,000 plan cuts, 344-county exit, and 53.1% YTD rally no longer appear.
- The 2027 landscape-file economics — the ~2.48% final rate notice vs. the 0.09% January proposal, and the SNP mix-shift behind the "16% premium drop" headline, are gone.
- All four prior "what surprised us" bullets (premium mix-shift trick, market celebrating member abandonment, OptumRx self-regulation, Cigna as cheapest-dodged-government-programs) — none carried forward.
Unchanged
- The MCR guide mechanics: 88.1% ±25bps full-year guide, above 88.35% = no Q4 room. Carried verbatim into the UNH section below — don't reread it there.
Star ratings: CMS just redistributed 2028's MA profit pool (New this cycle)
This is the new center of gravity. The 2027 star ratings release was the sector's biggest single repricing event of the cycle — and it moved money by administrative formula, not by premium or denial policy.
"Could net Humana $3 billion or more in extra revenue in 2028."
— TD Cowen's Ryan Langston in Star Ratings Reprice the Sector
The average rating slipped to 3.99 from 4.01; only ~37% of MA plans with drug coverage earned 4+ stars for 2027, down from 44% — the predictable result of CMS's tightened methodology (new measures, reweights, raised cutpoints). The winners/losers table from Healthcare Dive's analysis: Humana 41%→93% (company figure: 95%, "up from just 20% in 2026"); UnitedHealth 81%→68%; CVS/Aetna 84%→67%; Alignment 98%→25%; HCSC 52%→13%. Evercore ISI's Elizabeth Anderson puts Humana's 2028 bonus at $4.8 billion (CNBC).
This is the topic's thesis in its purest form: a quality-rating release — not a premium hike, not a denial-policy change — moved Humana's equity by billions in one session because the 4-star threshold gates bonus payments and rebate flexibility. The "insurers just deny claims and pocket premiums" narrative misses this mechanism entirely; the profit engine is the regulated bonus architecture.
What to watch: Alignment's threatened litigation — its president Dawn Maroney said, "We intend to pursue all available administrative remedies and to litigate the measures and methodologies we believe warrant review," which would open a new front testing the 2027 methodology changes (watch the thread).
Humana: the reversal is real, but read the fine print on where the bonus goes (Promoted)
Last cycle you knew Humana only as a plan-cutter near a 52-week high. The stars release explains why, and flips its story: margin compression — a 0.9% net margin, stars collapsing from 94% of members in 4+ star plans in 2024 to 20% in 2026 — just reversed.
"The boost to profits will depend on reinvestment in member benefits and arrangements with healthcare providers."
— Baird in Humana's Stars Reversal
The stock jumped 11.6% in a day to $431.87, a 52-week high on 3.3x average volume, now 45.8% above its 200-day moving average at a 40.8 P/E — against trailing fundamentals of negative Q2 operating cash flow (-$426M) (HUM market view). J.P. Morgan's Lisa Gill called it "a clear win for a company that has been working toward this outcome for several years" (CNBC). The Baird caveat is the honest one: bonus dollars largely get bid back into benefits to compete for members — that's how the MA bonus mechanism works, and it's why a $3–4.8B revenue windfall doesn't translate dollar-for-dollar into margin.
What to watch: Whether Humana's 2027 benefit bids for the 2028 bonus year reinvest the windfall competitively — the spread between bonus revenue and reinvestment is the actual margin recovery.
UnitedHealth: the stars step-down sets up tomorrow's MCR test (Escalated)
The MCR guide you already know is unchanged: 88.1% ±25bps, with anything above 88.35% meaning Q4 spending has no room. What's new is the second variable stacked on top of tomorrow's October 13 print — UNH's 4+ star share fell from 81% to 68% (J.P. Morgan estimates ~67%), so the 2028 bonus drag lands on the 2027 contraction already formalized (390,000 members' plans discontinued; Leerink's ~13% of plans dropped across 18 states).
"Manageable, especially because their enrollment in 4-plus star plans is still at the higher end compared to their peers."
— J.P. Morgan's Lisa Gill in UnitedHealth: Stars Step-Down
The stock sits at $379.30, down 17.3% from its July high, though the company has beaten estimates four straight quarters, most recently Q2 EPS of $6.38 versus $4.94 expected (UNH market view). The framing from last cycle extends: the popular narrative centers on denials and vertical-integration power, while what investors will actually parse tomorrow is a regulated MLR guide, reserve development, and the CMS-dented bonus pipeline. The Optum services leg, not the insurance margin, remains where the structural profit sits.
What to watch: Tomorrow's print — anything above an 88.35% MCR guide means Q4 spending has no room, and the margin-rebuild story wobbles (watch the thread).
The PBM structural threat gets its day in court — at the state level, not the federal one (Promoted)
The federal endgame you read last cycle is over — settled into conduct remedies — so this section picks up the one thread that was left dangling: the Arkansas ownership ban, previously described as "stalled," was heard by the Eighth Circuit on September 22 in Express Scripts v. Richmond.
"When pharmacy benefit managers own their own pharmacies, that creates an irresistible opportunity for those PBMs to engage in predatory and anti-competitive practices."
— Arkansas attorney Joseph Nelson in PBM Pharmacy-Ownership Bans
PBM counsel Jeffrey B. Wall called the law "as clear a violation as this court will ever see" under the Dormant Commerce Clause, quoting a sponsor — "we don't want these big companies, these big box stores, sucking our business and taking it out of Arkansas" — and flagging last-minute Walmart carve-outs as showing the law's true target. The stakes: "You're talking one-in-five Arkansans who're going to have to find a different place to get their medicines," with upwards of 50 pharmacy closures affecting five to six million prescriptions a year in the record. A ruling either way sets the constitutional template for whether states can force divestiture of the integrated pharmacy flywheel — the part of the PBM profit center state governments can actually reach, alongside spread-pricing enforcement like Arkansas Act 990's $10,000-per-violation damages. The panel's two Trump appointees pressing the state suggests it's genuinely contested.
What to watch: The Eighth Circuit ruling, expected in the coming months — it either constitutionalizes the ownership-ban playbook for other states or forecloses it.
What surprised us
- [NEW] The sector's biggest profit event of the cycle was a spreadsheet release. CMS publishing star ratings moved Humana by billions in a day — no drug launch, no acquisition, no premium change. MA margins are administratively determined, and no popular narrative about insurers captures that.
- [NEW] The giants' stars step-down barely dented the bull case. UNH down 13 points of 4-star share, CVS down 17 — and the analyst read is "manageable" because both still sit near the top of the peer table (Healthcare Dive). Scale in the bonus system is its own cushion.
- [NEW] Alignment's collapse may produce the next litigation wave. The company lost 73 points of 4+ star share in one release and immediately threatened to sue — the same playbook Humana ran (and lost) on the 2025 ratings.
- [NEW] The Walmart carve-out is the tell. The PBM side's own argument that Arkansas's law was protectionist rests on the state exempting the biggest retail pharmacy in America — vertical-integration politics makes for strange alliances on both sides (Courthouse News).
Open threads
- Carried forward, maturing tomorrow: the UNH Q3 MCR thread from last cycle is still open and now has a date — the October 13 print resolves it. It has absorbed the new stars variable (bonus-pipeline drag) alongside the original 88.1% test.
- New thread: [watch] Alignment Healthcare files suit over 2027 star ratings downgrade — worth a vote on whether a filing would be a genuine methodology test or a repeat of Humana's failed 2025-ratings challenge.
- No threads closed since last cycle; the prior briefing's single thread simply matured into this cycle's UNH section.